Onkologia:Anoikis resistanssi . Anoikis on rintasyöpämetastasoinnin transkriptionaali suppressori eli vaimentaja ykkönen(1)

 Anoikis, mikä se on? Anoikis prosessi on inadekvaattia kiinnittymistä, adheesiota, substraattiin . Anoikis prosessin säätelystä  ja metastaasiprosessin  vaimentamisesta  on kyse Geeni BRMS1 funktiossa. Kts.artikkeli:  https://pubmed.ncbi.nlm.nih.gov/30409762/

HAKU Gene Cards: 28.11. 2023

Aliases for BRMS1 Gene

• GeneCards Symbol: BRMS1 ²
• BRMS1 Transcriptional Repressor And Anoikis Regulator ^{2 3 5}
• Breast Cancer Metastasis Suppressor 1 ^{2 3}
• Breast Cancer Metastasis-Suppressor 1 ^{3 4}
• DKFZP564A063 ^{2 5}

External Ids for BRMS1 Gene

• HGNC: 17262
• NCBI Gene: 25855
• Ensembl: ENSG00000174744
• OMIM®: 606259
• UniProtKB/Swiss-Prot: Q9HCU9

NCBI Gene Summary for BRMS1 Gene

• This gene reduces the metastatic potential, but not the tumorogenicity, of human breast cancer and melanoma cell lines. The protein encoded by this gene localizes primarily to the nucleus and is a component of the mSin3a family of histone deacetylase complexes (HDAC). The protein contains two coiled-coil motifs and several imperfect leucine zipper motifs. Alternative splicing results in two transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]

GeneCards Summary for BRMS1 Gene

BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator) is a Protein Coding gene. Diseases associated with BRMS1 include Breast Cancer and Melanoma. Among its related pathways are Infectious disease and Chromatin organization. Gene Ontology (GO) annotations related to this gene include histone deacetylase binding and histone deacetylase activity. An important paralog of this gene is BRMS1L.

UniProtKB/Swiss-Prot Summary for BRMS1 Gene

Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma. ( BRMS1_HUMAN,Q9HCU9 ) 

Protein details for BRMS1 Gene (UniProtKB/Swiss-Prot)

Protein Symbol:

Q9HCU9-BRMS1_HUMAN

Recommended name: Breast cancer metastasis-suppressor 1

Protein attributes for BRMS1 Gene

Size:246 amino acids

Molecular mass:28461 Da

Protein existence level:PE1

Quaternary structure:

• Homohexamer (Potential).
  Interacts with SNX6, HDAC1 and RELA.
  Interacts with ARID4A.
  Identified in mSin3A corepressor complexes together with SIN3A, SIN3B, RBBP4, RBBP7, SAP30, SUDS3, ARID4A, HDAC1 and HDAC2.
  Interacts with SPOP; this recruits the protein to a ubiquitin ligase complex containing SPOP and CUL3.

 

Post-translational modifications for BRMS1 Gene

• Ubiquitinated by a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex containing SPOP, leading to proteasomal degradation. ( Q9HCU9-BRMS1_HUMAN )
• Ubiquitination at Lys123 ( NX_Q9HCU9 [NX_Q9HCU9-1] )
• Modification sites at PhosphoSitePlus ( Q9HCU9 ) 

Molecular function for BRMS1 Gene according to UniProtKB/Swiss-Prot

Function:

• Transcriptional repressor.
  Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'.
  Promotes HDAC1 binding to promoter regions.
  Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B.
  Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis.
  May be a mediator of metastasis suppression in breast carcinoma. BRMS1_HUMAN,Q9HCU9

 

	SuperPathway	Contained pathways
1	Infectious disease	Infectious disease 0.80 Viral Infection Pathways 0.80	Disease 0.55
2	Chromatin organization	Chromatin modifying enzymes 0.52	Chromatin organization 0.52
3	SARS-CoV-2 Infection	SARS-CoV Infections 0.72
4	RNA Polymerase I Promoter Opening	HDACs deacetylate histones 0.61
5	Potential therapeutics for SARS	Potential therapeutics for SARS -